Shadidi Mohsen, Sioud Mouldy
Department of Immunology, Molecular Medicine Group, The Norwegian Radium Hospital, Institute for Cancer Research, Montebello, N0310 Oslo, Norway.
Drug Resist Updat. 2003 Dec;6(6):363-71. doi: 10.1016/j.drup.2003.11.002.
To establish efficient and reliable therapeutic delivery into cancer cells, a number of delivery agents and concepts have been investigated in the recent years. Among many improvements in targeted and controlled delivery of therapeutics, cell-targeting peptides have emerged as the most valuable non-immunogenic approach to target cancer cells. Peptides can be incorporated into multicomponent gene-delivery complexes for cell-specific targeting. In contrast to larger molecules such as monoclonal antibodies, peptides have an excellent tumor penetration, which make them ideal carriers of therapeutics to the site of primary tumor and the distant metastatic sites. Here we give an update on the progress made during the last two years on the identification and potential of specific synthetic tumor targeting peptides.
为了建立高效且可靠的向癌细胞递送治疗药物的方法,近年来人们研究了许多递送剂和理念。在治疗药物的靶向和可控递送的诸多改进中,细胞靶向肽已成为靶向癌细胞最有价值的非免疫原性方法。肽可被整合到多组分基因递送复合物中以实现细胞特异性靶向。与单克隆抗体等较大分子相比,肽具有出色的肿瘤穿透能力,这使其成为将治疗药物递送至原发性肿瘤部位和远处转移部位的理想载体。在此,我们介绍过去两年在特定合成肿瘤靶向肽的鉴定及其潜力方面取得的进展。